Why should we still care about the stavudine dose?
Current recommendations advise that stavudine be phased out of use. The logistics and cost of switching are significant, and the World Health Organization has forecast that 1.55 million people will still be on stavudine-based antiretroviral therapy by the end of 2012. Stavudine is co-formulated in m...
Saved in:
Main Authors: | Steve Innes (Author), Mark Cotton (Author), Francois Venter (Author) |
---|---|
Format: | Book |
Published: |
AOSIS,
2011-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Low-dose stavudine trials: a public health priority for developing countries
by: W D Francois Venter, et al.
Published: (2012) -
Why it's time to say goodbye to stavudine ... everywhere
by: Isabelle Andrieux-Meyer, et al.
Published: (2012) -
Why we should be worried about the future of nutrition
by: Sushmitha Mahantshetti, et al.
Published: (2023) -
Why should we be concerned about early menarche?
by: Hae Sang Lee
Published: (2021) -
Why we should know about children´s and adolescent´s rights?
by: Abigail Casas-Muñoz, et al.
Published: (2014)